Addiction (Addiction )

Publisher: Society for the Study of Addiction to Alcohol and Other Drugs, Blackwell Publishing

Description

Addiction was established in 1884 and has been in continuous publication ever since the longest established journal in its field. It has built up a reputation in that time for scientific quality for the diversity of material it publishes and for its pioneering role in stimulating and leading debate. It is committed to promoting communication - between disciplines between cultures and between scientists practitioners and policy-makers. Addiction has been successful in these goals because of the huge cast of top specialists throughout the world who contribute to its work through their rigorous peer reviewing writing advice and support in many other ways. We have strengthened commitment to internationalism and to our authors by recently establishing regional offices for the Americas and for Australasia to speed the handling of papers and bring authors and editors closer. Addiction also receives wide media coverage internationally.

  • Impact factor
    4.58
  • 5-year impact
    4.95
  • Cited half-life
    7.20
  • Immediacy index
    1.32
  • Eigenfactor
    0.03
  • Article influence
    1.68
  • Website
    Addiction website
  • Other titles
    Addiction (Abingdon, England: Online)
  • ISSN
    1360-0443
  • OCLC
    37914840
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Blackwell Publishing

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • Some journals impose embargoes typically of 6 or 12 months, occasionally of 24 months
    • no listing of affected journals available as yet
  • Conditions
    • See Wiley-Blackwell entry for articles after February 2007
    • Publisher version cannot be used
    • On author or institutional or subject-based server
    • Server must be non-commercial
    • Publisher copyright and source must be acknowledged with set statement ("The definitive version is available at www.blackwell-synergy.com ")
    • Articles in some journals can be made Open Access on payment of additional charge
    • 'Blackwell Publishing' is an imprint of 'Wiley-Blackwell'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsTo examine changes in the evidence on the adverse health effects of cannabis since 1993.MethodsA comparison of the evidence in 1993 with the evidence and interpretation of the same health outcomes in 2013.ResultsResearch in the past 20 years has shown that driving while cannabis-impaired approximately doubles car crash risk and that around one in 10 regular cannabis users develop dependence. Regular cannabis use in adolescence approximately doubles the risks of early school-leaving and of cognitive impairment and psychoses in adulthood. Regular cannabis use in adolescence is also associated strongly with the use of other illicit drugs. These associations persist after controlling for plausible confounding variables in longitudinal studies. This suggests that cannabis use is a contributory cause of these outcomes but some researchers still argue that these relationships are explained by shared causes or risk factors. Cannabis smoking probably increases cardiovascular disease risk in middle-aged adults but its effects on respiratory function and respiratory cancer remain unclear, because most cannabis smokers have smoked or still smoke tobacco.Conclusions The epidemiological literature in the past 20 years shows that cannabis use increases the risk of accidents and can produce dependence, and that there are consistent associations between regular cannabis use and poor psychosocial outcomes and mental health in adulthood.
    Addiction 11/2014;
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • Addiction 11/2014; 109(11).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The World Health Organization estimates that 1 billion people will die from tobacco-related illnesses this century. Most health-care providers, however, fail to treat tobacco dependence. This may be due in part to the treatment ‘default’. Guidelines in many countries recommend that health-care providers: (i) ask patients if they are ‘ready’ to quit using tobacco; and (ii) provide treatment only to those who state they are ready to quit. For other health conditions—diabetes, hypertension, asthma and even substance abuse—treatment guidelines direct health-care providers to identify the health condition and initiate evidence-based treatment. As with any medical care, patients are free to decline—they can ‘opt out’ from care. If patients do nothing, they will receive care. For tobacco users, however, the treatment default is often that they have to ‘opt in’ to treatment. This drastically limits the reach of tobacco treatment because, at any given encounter, a minority of tobacco users will say they are ready to quit. As a result, few are offered treatment. It is time to change the treatment default for tobacco dependence. All tobacco users should be offered evidence-based care, without being screened for readiness as a precondition for receiving treatment. Opt-out care for tobacco dependence is warranted because changing defaults has been shown to change choices and outcomes for numerous health behaviors, and most tobacco users want to quit; there is little to no evidence supporting the utility of assessing readiness to quit, and an opt-out default is more ethical.
    Addiction 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The World Health Organization's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) has strong support as a clinical screening tool and research instrument, but has only been validated with adults. This study evaluated the ASSIST and ASSIST-Lite in an adolescent population.
    Addiction 10/2014;
  • Source
    Addiction 10/2014; 109(10).
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsTo understand the environmental and contextual influences of illicit cocaine and heroin use and craving using mobile health (mHealth) methods.DesignInteractive mHealth methods of ecological momentary assessment (EMA) were utilized in the Exposure Assessment in Current Time (EXACT) study to assess drug use and craving among urban drug users in real-time. Participants were provided mobile devices and asked to self-report every time they either craved (without using) or used heroin or cocaine for 30-days from November 2008 through May 2013.SettingBaltimore, Maryland, USAParticipants109 participants from the AIDS Linked to the IntraVenous Experience (ALIVE) studyMeasurementsFor each drug use or crave event, participants answered questions concerning their drug use, current mood, and their social, physical and activity environments. Odds ratios of drug use versus craving were obtained from logistic regression models with generalized estimating equations of all reported events.FindingsParticipants were a median of 48.5 years old, 90% African American, 52% male and 59% HIV-infected. Participants were significantly more likely to report use rather than craving drugs if they were with someone who was using drugs (aOR=1.45, 95% CI: 1.13,1.86), in an abandoned space (aOR=6.65, 95% CI: 1.78, 24.84) or walking/wandering (aOR=1.68, 95% CI: 1.11,2.54). Craving drugs was associated with being with a child (aOR=0.26, 95% CI: 0.12,0.59), eating (aOR=0.54, 95% CI: 0.34,0.85) or being at the doctor's office (aOR=0.31, 95% CI: 0.12, 0.80).Conclusions There are distinct drug using and craving environments among urban drug users, which may provide a framework for developing real-time context-sensitive interventions.
    Addiction 10/2014;
  • Addiction 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsWe formally estimate future smoking-attributable mortality up to 2050 for the total national populations of England & Wales, Denmark and the Netherlands, providing an update and extension of the descriptive smoking-epidemic model.Methods We used smoking prevalence and population-level lung-cancer mortality data for England & Wales, Denmark and the Netherlands, covering the period 1950 to 2009. To estimate the future smoking-attributable mortality fraction (SAF) we: (1) project lung cancer mortality by extrapolating age-period-cohort trends, using the observed convergence of smoking prevalence and similarities in past lung cancer mortality between men and women as input; (2) add other causes of death attributable to smoking by applying a simplified version of the indirect Peto-Lopez method to the projected lung cancer mortality.FindingsThe SAF for men in 2009 was 19% (44,872 deaths) in England & Wales, 22% (5,861 deaths) in Denmark and 25% (16,385 deaths) in the Netherlands. In our projections, these fractions decline to 6%, 12% and 14%, respectively, in 2050. The SAF for women peaked at 14% (38,883 deaths) in 2008 in England & Wales, and is expected to peak in 2028 in Denmark (22%) and in 2033 in the Netherlands (23%). By 2050, a decline to 9%, 17% and 19%, respectively, is foreseen. Different indirect estimation methods of the SAF in 2050 yield a range of 1-8% (England & Wales), 8-13% (Denmark), and 11-16% (the Netherlands) for men, and 7-16%, 12-26%, and 13-31%, for women.Conclusions From Northern European data we project that smoking-attributable mortality will remain important for the future, especially for women. Whereas substantial differences between countries remain, the age-specific evolution of smoking-attributable mortality stays similar across countries and between sexes.
    Addiction 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsTo evaluate trends in use of stop-smoking medications (SSMs) before and after varenicline (Chantix™) was introduced to the marketplace in the United States (US), and to determine whether varenicline reached segments of the population unlikely to use other SSMs.DesignCohort surveySettingUnited StatesParticipantsA nationally representative sample of adult smokers in the US interviewed as part of the International Tobacco Control Four Country Survey between 2004 and 2011. Primary analyses used cross-sectional data from 1737 smokers who attempted to quit (∼450 per wave).MeasurementsReporting an attempt to quit smoking; use of each of the following types of SSMs for the purpose of quitting smoking: nicotine gum, nicotine patch, other nicotine replacement therapy, bupropion, and varenicline.FindingsThere was a significant increase in the rate of use of any SSM among quit attempters across the study period (OR=1.15, 95% CI = 1.10-1.21 per year). This increase was largest after varenicline was introduced (OR=1.16, 95% CI= 1.07-1.26 per year); however, there was a decline in use of nicotine patch during this time (OR=0.87, 95% CI=0.76-0.99 per year). Varenicline users were generally similar to users of other SSMs but differed from those who did not use any SSMs in that they tended to be older (OR=5.46, p=0.024), to be white (OR=2.33, p=0.002), to have high incomes (OR=1.85, p=0.005), to have high nicotine dependence prior to quitting (OR=2.40, p=0.001), and to have used medication in the past (OR=3.29, p<.001).Conclusions The introduction of varenicline in the US coincided with a net increase in attempts to quit smoking, and, among these, a net increase in use of stop-smoking medications. The demographic profile of varenicline users is similar to the profile of those who use other stop-smoking medications and different from the profile of those who attempt to quit without any medication.
    Addiction 10/2014;
  • Source
    Addiction 10/2014; 109(10).